Truist raised the firm’s price target on Pennant Group to $38 from $34 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services. The firm is introducing 2026 estimates and 2025 quarterly estimates across several verticals while also adjusting its model estimates on select names, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks